BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 24842011)

  • 1. [Prognostic significance of mutually exclusive expression of ERG and SPINK1 in endocrine-treated prostatic cancer].
    Teng L; Gao W; Lu D; Xu J; Zhao L
    Zhonghua Bing Li Xue Za Zhi; 2014 Mar; 43(3):149-53. PubMed ID: 24842011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrine-treated prostate cancer.
    Leinonen KA; Tolonen TT; Bracken H; Stenman UH; Tammela TL; Saramäki OR; Visakorpi T
    Clin Cancer Res; 2010 May; 16(10):2845-51. PubMed ID: 20442300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients.
    Brooks JD; Wei W; Hawley S; Auman H; Newcomb L; Boyer H; Fazli L; Simko J; Hurtado-Coll A; Troyer DA; Carroll PR; Gleave M; Lance R; Lin DW; Nelson PS; Thompson IM; True LD; Feng Z; McKenney JK
    PLoS One; 2015; 10(7):e0132343. PubMed ID: 26172920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The expression profile and prognostic value of SPINK1 in initially diagnosed bone metastatic prostate cancer.
    Pan X; Zhang X; Gong J; Tan J; Yin X; Tang Q; Shu K; Shen P; Zeng H; Chen N
    Prostate; 2016 Jun; 76(9):823-33. PubMed ID: 27159572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancer.
    Terry S; Nicolaiew N; Basset V; Semprez F; Soyeux P; Maillé P; Vacherot F; Ploussard G; Londoño-Vallejo A; de la Taille A; Allory Y
    Cancer; 2015 May; 121(9):1422-30. PubMed ID: 25639219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence.
    Grupp K; Diebel F; Sirma H; Simon R; Breitmeyer K; Steurer S; Hube-Magg C; Prien K; Pham T; Weigand P; Michl U; Heinzer H; Kluth M; Minner S; Tsourlakis MC; Izbicki JR; Sauter G; Schlomm T; Wilczak W
    Prostate; 2013 Nov; 73(15):1690-8. PubMed ID: 23843146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SPINK1 expression in relation to PTEN and ERG in matched primary and lymph node metastatic prostate cancer: Implications for biomarker development.
    Huang KC; Bégin LR; Palanisamy N; Donnelly B; Bismar TA
    Urol Oncol; 2016 May; 34(5):235.e1-10. PubMed ID: 26725250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.
    Tomlins SA; Alshalalfa M; Davicioni E; Erho N; Yousefi K; Zhao S; Haddad Z; Den RB; Dicker AP; Trock BJ; DeMarzo AM; Ross AE; Schaeffer EM; Klein EA; Magi-Galluzzi C; Karnes RJ; Jenkins RB; Feng FY
    Eur Urol; 2015 Oct; 68(4):555-67. PubMed ID: 25964175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SPINK1 Overexpression in Localized Prostate Cancer: a Rare Event Inversely Associated with ERG Expression and Exclusive of Homozygous PTEN Deletion.
    Huang KC; Evans A; Donnelly B; Bismar TA
    Pathol Oncol Res; 2017 Apr; 23(2):399-407. PubMed ID: 27738792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clonal evaluation of prostate cancer foci in biopsies with discontinuous tumor involvement by dual ERG/SPINK1 immunohistochemistry.
    Fontugne J; Davis K; Palanisamy N; Udager A; Mehra R; McDaniel AS; Siddiqui J; Rubin MA; Mosquera JM; Tomlins SA
    Mod Pathol; 2016 Feb; 29(2):157-65. PubMed ID: 26743468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers.
    Dhani NC; Emmenegger U; Adams L; Jongstra J; Tannock IF; Sridhar SS; Knox JJ; Day JR; Groskopf J; Joshua AM
    BJU Int; 2012 Sep; 110(6):840-5. PubMed ID: 22313860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer.
    Leinonen KA; Saramäki OR; Furusato B; Kimura T; Takahashi H; Egawa S; Suzuki H; Keiger K; Ho Hahm S; Isaacs WB; Tolonen TT; Stenman UH; Tammela TL; Nykter M; Bova GS; Visakorpi T
    Cancer Epidemiol Biomarkers Prev; 2013 Dec; 22(12):2333-44. PubMed ID: 24083995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of ERG protein, a prostate cancer specific marker, in high grade prostatic intraepithelial neoplasia (HGPIN): lack of utility to stratify cancer risks associated with HGPIN.
    He H; Osunkoya AO; Carver P; Falzarano S; Klein E; Magi-Galluzzi C; Zhou M
    BJU Int; 2012 Dec; 110(11 Pt B):E751-5. PubMed ID: 23046279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ERG protein expression reflects hormonal treatment response and is associated with Gleason score and prostate cancer specific mortality.
    Bismar TA; Dolph M; Teng LH; Liu S; Donnelly B
    Eur J Cancer; 2012 Mar; 48(4):538-46. PubMed ID: 22300588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma.
    Bhalla R; Kunju LP; Tomlins SA; Christopherson K; Cortez C; Carskadon S; Siddiqui J; Park K; Mosquera JM; Pestano GA; Rubin MA; Chinnaiyan AM; Palanisamy N
    Mod Pathol; 2013 Jun; 26(6):835-48. PubMed ID: 23348902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HOXB13 G84E-related familial prostate cancers: a clinical, histologic, and molecular survey.
    Smith SC; Palanisamy N; Zuhlke KA; Johnson AM; Siddiqui J; Chinnaiyan AM; Kunju LP; Cooney KA; Tomlins SA
    Am J Surg Pathol; 2014 May; 38(5):615-26. PubMed ID: 24722062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined analysis of TMPRSS2-ERG and TERT for improved prognosis of biochemical recurrence in prostate cancer.
    Sabaliauskaite R; Jarmalaite S; Petroska D; Dasevicius D; Laurinavicius A; Jankevicius F; Lazutka JR
    Genes Chromosomes Cancer; 2012 Aug; 51(8):781-91. PubMed ID: 22505341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SPINK1 protein expression and prostate cancer progression.
    Flavin R; Pettersson A; Hendrickson WK; Fiorentino M; Finn S; Kunz L; Judson GL; Lis R; Bailey D; Fiore C; Nuttall E; Martin NE; Stack E; Penney KL; Rider JR; Sinnott J; Sweeney C; Sesso HD; Fall K; Giovannucci E; Kantoff P; Stampfer M; Loda M; Mucci LA
    Clin Cancer Res; 2014 Sep; 20(18):4904-11. PubMed ID: 24687926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ERG positive prostatic cancer may show a more angiogenetic phenotype.
    Strzępek A; Kaczmarczyk K; Białas M; Szpor J; Dyduch G; Szopiński T; Chłosta P; Okoń K
    Pathol Res Pract; 2014 Dec; 210(12):897-900. PubMed ID: 25220615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of ERG and SPINK1 expression among incidental and metastatic prostate cancer in Japanese men.
    Koide H; Kimura T; Inaba H; Sato S; Iwatani K; Yorozu T; Furusato B; Kamata Y; Miki J; Kiyota H; Takahashi H; Egawa S
    Prostate; 2019 Jan; 79(1):3-8. PubMed ID: 30051483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.